CYCC Shares Continue To Stand Out In Pre-Market Trading

By Monica Gerson
Benzinga Staff Writer
January 08, 2010 10:29 AM

Symbols: CYCC

Posted in: Long Ideas, News, Intraday Update, Trading Ideas

Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) continued to move up in pre-market trading today. CYCC announced positive preclinical results for its drug candidate, seliciclib, yesterday.

The preclinical tests showed that seliciclib may be effective in killing hard-to-treat lung cancers. An article published in a medical journal indicated that seliciclib was significantly more effective against chronic lymphocytic leukemia cells than older chemotherapy drugs.

CYCC’s shares have gained 17.10% to $3.13 in today’s pre-market trading.

< Previous
China Mobile (CHL) & Nokia (NOK) on Tim Seymour's Watchlist

Next >
Potential Margin Improvement Not Reflected in DAN’s Share Price

Printer-friendly version

Send to friend

We're Loving

Yahoo!'s Interim CEO Doing the Right Things

Why History Favors the Bulls

How to Deal With Workplace Stress

You Could Have Profited 14% on AOL by Using Benzinga Pro. Try It for Free Now!

Goldman Investment Shines Light on Solar Power

Benzinga's Premium Memberships

Options & Volatility Edge

Options & Volatility Edge is for those people who want to make money using cost effective options trading strategies. This product is for anyone—novices and experts. If you understand how to enter an options trade, you need Options & Volatility Edge.

Learn More >>
14 Day Free Trial!

Basic Premium
ETF Professor

The ETF Professor is truly an appropriate moniker, because the Professor spends hours everyday analyzing the charts of dozens of ETFs EVERY DAY.

Learn More >>
14 Day Free Trial!

Basic Premium
Winning Stocks

Winning Stocks tracks and analyzes attractive stocks that are poised to make great returns for the average investor. Investors receive the right information at the right time, which provides them with the possibility for great gains and the potential to beat the market.

Learn More >>
14 Day Free Trial!

Basic Premium

Real-Time Rumors

In this game, information is everything. You have to know what is happening before the Street begins trading against you utilizing the new information. We will provide you with that edge.

Learn More >>
14 Day Free Trial!

Basic Premium
Chart-Caster

From novice to pro, Chart-Caster delivers over $11,000 per month* in profitable trade setups across all time-frames from which members can evaluate, select, and replicate within their own trading accounts.

Learn More >>
14 Day Free Trial!

Basic Premium

CYCC Shares Continue To Stand Out In Pre-Market Trading

Benzinga's Premium Memberships

More stories by Monica Gerson

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social